This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nakashima, L. Search for Related Content PubMed Articles by Nakashima, L. Social Bookmarking                   What's this?

Guidelines for the treatment of hypercalcemia associated with malignancy

B.C. Cancer Agency, Vancouver Cancer Centre, Pharmacy Department, Vancouver, British Columbia, Canada

Hypercalcemia is a common complication of cancer and occurs in 10—20% of patients. Although treatment of the underlying cancer is the optimal therapy, this may not be prac tical or available for many patients. This re port details our approach to the management of hypercalcemia at the British Columbia Can cer Agency, Vancouver Cancer Centre. The recommended approach to therapy is hydra tion followed by pamidronate and if needed, calcitonin. If no response is noted, plicamy cin may be used as a second line agent. In patients with multiple myeloma and lym phoma, prednisone is also suggested.

Key Words: Hypercalcemia • guidelines • bisphosphonates.

Journal of Oncology Pharmacy Practice, Vol. 3, No. 1, 31-37 (1997)
DOI: 10.1177/107815529700300105


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?